ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.33 Average PT from Analysts

Posted by Stanley Muller on Aug 7th, 2026

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $7.3333.

Several equities research analysts have issued reports on PRQR shares. Wall Street Zen downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. JonesTrading dropped their price objective on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Weiss Ratings cut shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Finally, Chardan Capital reduced their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, June 26th.

Get Our Latest Report on ProQR Therapeutics

Insider Activity

In related news, CEO Boer Daniel Anton De acquired 150,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was purchased at an average cost of $1.74 per share, for a total transaction of $261,000.00. Following the completion of the transaction, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $522,000. The trade was a 100.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bart Filius acquired 150,000 shares of the business’s stock in a transaction on Friday, July 17th. The shares were bought at an average price of $1.72 per share, with a total value of $258,000.00. Following the completion of the transaction, the director directly owned 300,000 shares of the company’s stock, valued at approximately $516,000. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 600,000 shares of company stock worth $988,500. Insiders own 8.40% of the company’s stock.

Institutional Trading of ProQR Therapeutics

Several hedge funds have recently added to or reduced their stakes in PRQR. Axiom Investment Management LLC acquired a new stake in ProQR Therapeutics during the 1st quarter worth approximately $53,000. Bank of America Corp DE grew its holdings in ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 11,186 shares in the last quarter. Walleye Capital LLC grew its holdings in ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 15,744 shares in the last quarter. Invesco Ltd. bought a new position in ProQR Therapeutics during the 4th quarter worth $51,000. Finally, XTX Topco Ltd increased its position in ProQR Therapeutics by 1,057.4% during the 4th quarter. XTX Topco Ltd now owns 117,900 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 107,713 shares during the period. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Stock Down 3.6%

PRQR opened at $1.90 on Tuesday. ProQR Therapeutics has a 12-month low of $1.33 and a 12-month high of $3.10. The stock has a market cap of $200.18 million, a price-to-earnings ratio of -3.80 and a beta of 0.07. The business has a 50 day moving average of $1.69 and a 200-day moving average of $1.65.

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last posted its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The business had revenue of $2.35 million for the quarter, compared to analyst estimates of $5.19 million. As a group, analysts expect that ProQR Therapeutics will post -0.52 earnings per share for the current year.

ProQR Therapeutics Company Profile

(Get Free Report)

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.